Tag Archives: BIO Events

Tekmira CEO Discusses Ebola Therapy Development at 2014 BIO Investor Forum

Tekmira CEO

Today at the 13th Annual BIO Investor Forum, Tekmira CEO Dr. Mark Murray participated in a conversation with Phyllis Arthur, BIO’s Senior Director for Vaccines, Immunotherapeutics, and Diagnostics Policy. Tekmira has been in the spotlight recently due to their experimental Ebola therapy, TKM-Ebola. Recently, they announced that FDA has allowed them to provide TKM-Ebola for treatment under expanded access protocols, and that they have joined an international consortium to conduct clinical trials of Ebola virus therapeutics Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Ken Drazan, MD

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, who serves as the head of Johnson & Johnson Innovation in California. The conversation was moderated by Deepa R. Pakianathan, PhD, a general partner for Delphi Ventures who leads the firm’s biotechnology investment activities. Ken Drazan has a unique viewpoint which results from having experience with both the biopharma start-up world as well as in the investment community. This background Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO 2015 – Call for Sessions Extended

115x76-cfs

It’s not too late to submit a session proposal for the 2015 BIO International Convention. We’ve just extended the submission deadline until Wednesday, October 8th at 5:00 pm EDT. All ideas are welcome! We seek proposals that reflect current trends and novel ideas in all focus areas Business Development & Finance Biomedical Technology: Research & Development Digital Health General Biotechnology Interest Intellectual Property Value, Market Access & Commercialization View the full list here. If you’d Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biotech CEOs Speak Out on JOBS Act Success

Biotech IPOs Infographic

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. The JOBS Act reached a major milestone last week, with the 100th company going public under its provisions. On October 7th at the 13th Annual BIO Investor Forum, we Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Looking Ahead to the 2014 BIO Investor Forum, Biotech IPO Hopefuls Continue to Seek Funding

partnering1

As mentioned in Fierce Biotech, a new crop of biotech IPO hopefuls have recently thrown their hats into the ring. These three biotechs are targeting $175M in IPO cash, hoping to secure funding for oncology, pain, and rare diseases. In fact, there have been 96 IPOs since the passage of the JOBS Act in April of 2012. One important provision of the Act is the ability for emerging growth companies to conduct “testing the waters” meetings with Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,